Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)

Market Cap	6.63B +62.8%
Revenue (ttm)	1.60B -14.2%
Net Income	-1.39B
EPS	-2.11
Shares Out	661.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,193,830
Open	9.83
Previous Close	9.80
Day's Range	9.73 - 10.15
52-Week Range	7.40 - 12.79
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sarsae, juice soda, soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides medical devices,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 2,769
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300147

Financial Performance

In 2025, Xiangxue Pharmaceutical's revenue was 1.60 billion, a decrease of -14.16% compared to the previous year's 1.86 billion. Losses were -1.39 billion, 62.2% more than in 2024.